Endocyte, Inc. (ECYT) Gains Following Clinical Update, Q2 Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update
July 30, 2014 2:49 PM EDTChardan Capital affirms Endocyte (Nasdaq: ECYT) at Buy with a price target of $15 following Q2 results and updated information of EC1456.
Analyst Ling Wang commented, ECYT reported 2Q14 EPS of $0.54, vs. consensus... More



